Antibodies targeting collapsin response-mediator protein-5 (CRMP5) notably affect the cerebellum and sensorimotor systems, characteristically clinically manifesting as cerebellar ataxia, uveitis, optic neuritis, with the potential to progress to encephalomyelitis (Table 5) [26]. This evidence concerns the gene DPYSL5 and encephalomyelitis.